Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Coagulation01:09

Coagulation

11.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
11.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

453
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
453
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

15.4K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
15.4K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

14.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nanomotors with Dual Targeting and Self-Feedback Degradation Performance for the Treatment of Sepsis.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

High-throughput characterization of transcription factors that modulate UV damage formation and repair at single-nucleotide resolution.

Nature communications·2026
Same author

NF-κB signaling pathway mediates the anti-tumor effect of Ginsenoside Rg1 in glioblastoma.

Biochemistry and biophysics reports·2026
Same author

Wearable micromotor-based electrochemical microneedle sensors for monitoring tumor biomarkers in skin.

Biosensors & bioelectronics·2026
Same author

Thrombus-targeting nanosystems: Differential performance in arterial and venous circulation.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Defect-Engineered IrO<sub>x</sub>@Perovskite Heterostructures via Thermal Reconstruction for Acid-Stable Oxygen Evolution Catalysis.

Small (Weinheim an der Bergstrasse, Germany)·2026

Related Experiment Video

Updated: Mar 16, 2026

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.3K

Poly(γ-glutamic acid), coagulation? Anticoagulation?

Tingting Xu1,2, Fang Peng2, Tao Zhang2

  • 1a State Key Laboratory of Materials-Oriented Chemical Engineering , College of Food Science and Light Industry, Nanjing Tech University , Nanjing , China.

Journal of Biomaterials Science. Polymer Edition
|August 23, 2016
PubMed
Summary

Poly(γ-glutamic acid) (γ-PGA), a hemostatic agent, demonstrates excellent anticoagulant properties and non-cytotoxicity when sufficiently hydrated. This dual functionality makes γ-PGA a versatile biomaterial for various biomedical applications.

Keywords:
Poly(γ-glutamic acid)anticoagulationcoagulationcytotoxicitywater-absorption

More Related Videos

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

9.3K
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.3K

Related Experiment Videos

Last Updated: Mar 16, 2026

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.3K
Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

9.3K
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.3K

Area of Science:

  • Biomaterials Science
  • Hemostasis and Thrombosis
  • Polymer Chemistry

Background:

  • Poly(γ-glutamic acid) (γ-PGA) is recognized for its hemostatic properties due to water absorption and locking.
  • The blood compatibility of hydrated γ-PGA, particularly its anticoagulant potential, remains less explored.

Purpose of the Study:

  • To investigate the anticoagulant properties of water-absorbed γ-PGA.
  • To evaluate the hemocompatibility and cytotoxicity of hydrated γ-PGA for potential biomedical use.

Main Methods:

  • In vitro coagulation tests.
  • Hemolytic assay.
  • Platelet adhesion and activation assays.
  • MTT assay for cytotoxicity.

Main Results:

  • Sufficiently hydrated γ-PGA exhibited significant anticoagulant properties.
  • Hemolytic assays and platelet studies indicated good hemocompatibility.
  • Cytotoxicity experiments confirmed the non-toxic nature of hydrated γ-PGA.

Conclusions:

  • Hydrated γ-PGA possesses favorable anticoagulant properties and exhibits non-cytotoxicity.
  • γ-PGA's dual hemostatic and anticoagulant capabilities position it as a promising biomaterial.
  • Tailored γ-PGA can be developed for diverse biomedical applications requiring controlled blood interaction.